| A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors (NCT05355753) | C4 Therapeutics, Inc. | 2022-03-25 |
| Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma (NCT05116800) | Brown University | 2022-03-01 |
| HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (NCT04995003) | Baylor College of Medicine | 2021-12-07 |
| A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas (NCT04906876) | Brown University | 2021-09-01 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (NCT04420975) | Jonsson Comprehensive Cancer Center | 2020-10-14 |
| B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT04483778) | Seattle Children's Hospital | 2020-07-13 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels (NCT04537715) | Epizyme, Inc. | 2020-04-23 |
| CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma (NCT04145700) | Eli Lilly and Company | 2020-03-04 |
| Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients (NCT04008238) | Institut Bergonié | 2020-01-06 |
| Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (NCT04044768) | USWM CT, LLC | 2019-08-13 |
| EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (NCT03618381) | Seattle Children's Hospital | 2019-06-18 |
| Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin (NCT03773510) | Italian Sarcoma Group | 2019-02-28 |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors (NCT03604783) | Sumitomo Pharma America, Inc. | 2018-12-26 |
| NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) (NCT03399448) | University of Pennsylvania | 2018-09-05 |
| Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas (NCT03989596) | Maria Sklodowska-Curie National Research Institute of Oncology | 2018-06-01 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma (NCT03250325) | Takara Bio Inc. | 2017-09-20 |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (NCT03016819) | Advenchen Laboratories, LLC | 2017-08-15 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922) | USWM CT, LLC | 2017-05-15 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall (NCT03651375) | Maria Sklodowska-Curie National Research Institute of Oncology | 2017-02-11 |
| DHEA in Synovial Sarcoma Patients (NCT02683148) | Washington University School of Medicine | 2016-09-13 |
| Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors (NCT02869217) | University Health Network, Toronto | 2016-09-01 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study (NCT02875548) | Epizyme, Inc. | 2016-08-30 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma (NCT02584309) | Washington University School of Medicine | 2016-02-22 |
| EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma (NCT02601937) | Epizyme, Inc. | 2016-01-07 |
| A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (NCT02601950) | Epizyme, Inc. | 2015-12-22 |
| Detection of Circulating Tumor Cells in Patients With Sarcomas (NCT02983539) | AC Camargo Cancer Center | 2015-10-01 |
| Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) (NCT02609984) | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2015-04-29 |
| T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies (NCT02457650) | Shenzhen Second People's Hospital | 2015-04-01 |
| Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (NCT02180867) | National Cancer Institute (NCI) | 2014-08-12 |
| Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases (NCT02181829) | Memorial Sloan Kettering Cancer Center | 2014-07-01 |
| Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma (NCT01957709) | Fred Hutchinson Cancer Center | 2013-09-25 |
| Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy (NCT01674101) | St. Jude Children's Research Hospital | 2012-09-01 |
| Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (NCT01241162) | University of Louisville | 2010-08-01 |
| Sorafenib and Dacarbazine in Soft Tissue Sarcoma (NCT00837148) | Memorial Sloan Kettering Cancer Center | 2009-02-01 |
| A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma (NCT00668148) | Eli Lilly and Company | 2008-07-01 |
| Bevacizumab and Radiation Therapy for Sarcomas (NCT00356031) | Massachusetts General Hospital | 2006-07-01 |
| A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma (NCT00140855) | Ludwig Institute for Cancer Research | 2005-06-08 |
| Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy (NCT00004853) | National Cancer Institute (NCI) | 2000-03-03 |
| Tazemetostat Expanded Access Program for Adults With Solid Tumors (NCT03874455) | Epizyme, Inc. | |